Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Oct;1(4):199-207.
doi: 10.1177/1756287209350315.

Management of the residual post-chemotherapy retroperitoneal mass in germ cell tumors

Hugh J Lavery  1 , Robert R Bahnson, David S Sharp, Kamal S Pohar
Affiliations

Management of the residual post-chemotherapy retroperitoneal mass in germ cell tumors

Hugh J Lavery et al. Ther Adv Urol. 2009 Oct.

Abstract

The management of the residual mass in the retroperitoneum following induction chemotherapy for metastatic testicular cancer has evolved over the past three decades. A multidisciplinary approach involving cisplatin-based chemotherapy and postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) has increased long-term survival rates above 80%. Advances into the appropriate patient selection and timing of surgery have lowered morbidity while improving oncologic outcomes. However, areas of controversy still exist within the field. Management of the small residual mass, predictors of the histology of the residual mass, the extent of PC-RPLND, the role of PC-RPLND in the setting of elevated serum tumor markers, and the role of positron-emission tomography are all topics of ongoing research and debate. We will discuss these issues and review the current guidelines for the management of the residual postchemotherapy retroperitoneal mass in this review.

Keywords: germ cell; neoplasm; post-chemotherapy; residual; retroperitoneal lymph node dissection; seminoma; testes.

PubMed Disclaimer

References

    1. Aprikian A.G., Herr H.W., Bajorin D.F., Bosl G.J. (1994) Resection of postchemotherapy residual masses and limited retroperitoneal lymphadenectomy in patients with metastatic testicular nonseminomatous germ cell tumor? Cancer 74: 1329–1334 - PubMed
    1. Beck S.D., Foster R.S., Bihrle R., Ulbright T., Koch M.O., Wahle G.R., et al. (2002) Teratoma in the orchiectomy specimen and volume of metastasis are predictors of retroperitoneal teratoma in post-chemotherapy nonseminomatous testis cance? J Urol 168: 1402–1404 - PubMed
    1. Beck S.D., Patel M.I., Sheinfeld J. (2004) Tumor marker levels in post-chemotherapy cystic masses: clinical implications for patients with germ cell tumor? J Urol 171: 168–171 - PubMed
    1. Beck S.D., Foster R.S., Bihrle R., Einhorn L.H., Donohue J.P. (2005) Outcome analysis for patients with elevated serum tumor markers at postchemotherapy retroperitoneal lymph node dissectio? J Clin Oncol 23: 6149–6156 - PubMed
    1. Beck S.D., Foster R.S., Bihrle R., Einhorn L.H., Donohue J.P. (2007a) Post chemotherapy RPLND in patients with elevated markers: current concepts and clinical outcom? Urol Clin N Am 34: 219–225 - PubMed

LinkOut - more resources